KPL-387 / Kiniksa Pharmaceuticals - LARVOL DELTA

Transition to KPL-387 Monotherapy Dosing & Administration Study (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: Kiniksa Pharmaceuticals International, plc | Not yet recruiting ➔ Recruiting

Enrollment open • Monotherapy • Cardiovascular • Heart Failure

KPL-387 (monoclonal antibody IL-1 receptor antagonist) (The Manila Times) - "Kiniksa is conducting a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis and expects data from the dose-focusing portion in the second half of 2026."

P2/3 data • Immunology

Transition to KPL-387 Monotherapy Dosing & Administration Study (clinicaltrials.gov) - P2 | N=80 | Not yet recruiting | Sponsor: Kiniksa Pharmaceuticals International, plc

Monotherapy • New P2 trial • Cardiovascular • Heart Failure

Phase 2/3 Study of KPL-387 in Recurrent Pericarditis (clinicaltrials.gov) - P2/3 | N=165 | Recruiting | Sponsor: Kiniksa Pharmaceuticals International, plc | Initiation date: Oct 2025 ➔ Jul 2025

Trial initiation date • Cardiovascular

KPL-387 (monoclonal antibody IL-1 receptor antagonist) (The Manila Times) - "Kiniksa expects data from the dose-focusing portion of the Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in the second half of 2026. Subsequently, Kiniksa plans to initiate the pivotal portion of the trial; Kiniksa continues to plan to conduct a supplemental Phase 2 Transition to KPL-387 Monotherapy Dosing & Administration Study evaluating the efficacy and safety of the dosing regimens used to transition patients from standard therapies to KPL-387 monotherapy."

New P2 trial • P2/3 data • Inflammation

Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis (Yahoo Finance) - "Data from the Phase 2 dose-focusing portion of the KPL-387 Phase 2/3 recurrent pericarditis trial are expected in the second half of 2026."

Orphan drug • P2/3 data • Cardiovascular

Phase 2/3 Study of KPL-387 in Recurrent Pericarditis (clinicaltrials.gov) - P2/3 | N=165 | Recruiting | Sponsor: Kiniksa Pharmaceuticals International, plc | Initiation date: Jul 2025 ➔ Oct 2025

Trial initiation date • Cardiovascular

Kiniksa Pharmaceuticals Reports...Recent Portfolio Execution (GlobeNewswire) - "Kiniksa is recruiting patients in the dose-focusing portion of the Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis. The company expects data from this portion of the trial in the second half of 2026. Subsequently, Kiniksa plans to initiate the pivotal portion of the trial."

P2/3 data • Trial status • Immunology • Inflammation

Phase 2/3 Study of KPL-387 in Recurrent Pericarditis (clinicaltrials.gov) - P2/3 | N=165 | Recruiting | Sponsor: Kiniksa Pharmaceuticals International, plc | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular

Phase 2/3 Study of KPL-387 in Recurrent Pericarditis (clinicaltrials.gov) - P2/3 | N=165 | Not yet recruiting | Sponsor: Kiniksa Pharmaceuticals International, plc

New P2/3 trial • Cardiovascular